|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM and Forman D: Bray F. Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
2
|
Colvin H, Mizushima T, Eguchi H, Takiguchi
S, Doki Y and Mori M: Gastroenterological surgery in Japan: The
past, the present and the future. Ann Gastroenterol Surg. 1:5–10.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pradhan A, Hammerquist AM, Khanna A and
Curran SP: The C box rgion of MAF1 regulates transcriptional
activity and protein stability. J Mol Biol. 429:192–207. 2017.
View Article : Google Scholar
|
|
4
|
Vannini A and Cramer P: Conservation
between the RNA poly merase I, II, and III transcription initiation
machineries. Mol Cell. 45:439–446. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
White RJ: RNA polymerases I and III, non
coding RNAs and cancer. Trends Genet. 24:622–629. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Khanna A, Pradhan A and Curran SP:
Emerging roles for MAF1 beyond the regulation of RNA polymerase III
activity HHS Public Access. J Mol Biol. 427:2577–2585. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Johnson SS, Zhang C, Fromm J, Willis IM
and Johnson DL: Mammalian Maf1 is a negative regulator of
transcription by all three nuclear RNA polymerases. Mol Cell.
26:3673792007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Palian BM, Rohira AD, Johnson SAS, He L,
Zheng N, Dubeau L, Stiles BL and Johnson DL: Maf1 is a novel target
of PTEN and PI3K signaling that negatively regulates oncogenesis
and lipid metabolism. PLoS Genet. 10:e10047892014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Khanna A, Pradhan A and Curran SP:
Emerging roles for Maf1 beyond the regulation of RNA polymerase III
activity. J Mol Biol. 427:2577–2585. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Y, Tsang CK, Wang S, Li XX, Yang Y, Fu
L, Huang W, Li M, Wang HY and Zheng XF: MAF1 suppresses AKT mTOR
signaling and liver cancer through activation of PTEN tran
scription. Hepatology. 63:1928–1942. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Watanabe T, Itabashi M, Shimada Y, Tanaka
S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, et
al: Japanese Society for Cancer of the Colon and Rectum: Japanese
Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010
for the treatment of colorectal cancer. Int J Clin Oncol. 17:1–29.
2012. View Article : Google Scholar
|
|
12
|
Sugimura K, Fujiwara Y, Omori T, Motoori
M, Miyoshi N, Akita H, Gotoh K, Kobayashi S, Takahashi H, Noura S,
et al: Clinical importance of a transcription reverse transcription
concerted (TRC) diagnosis using peritoneal lavage fluids obtained
pre and post lymphadenectomy from gastric cancer patients. Surg
Today. 46:654–660. 2016. View Article : Google Scholar
|
|
13
|
Newman AM, Liu CL, Green MR, Gentles AJ,
Feng W, Xu Y, Hoang CD, Diehn M and Alizadeh AA: Robust enumeration
of cell subsets from tissue expression profiles. Nat Methods.
12:453–457. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gentles AJ, Newman AM, Liu CL, Bratman SV,
Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD, et al: The
prognostic landscape of genes and infiltrating immune cells across
human cancers. Nat Med. 21:938–945. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Graczyk D, White RJ and Ryan KM:
Involvement of RNA poly merase III in immune responses. Mol Cell
Biol. 35:1848–1859. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chiu YH, Macmillan JB and Chen ZJ: RNA
polymerase III detects cytosolic DNA and induces type I interferons
through the RIG I pathway. Cell. 138:576–591. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim CG, Ahn JB, Jung M, Beom SH, Kim C,
Kim JH, Heo SJ, Park HS, Kim JH, Kim NK, et al: Effects of
microsatellite insta bility on recurrence patterns and outcomes in
colorectal cancers. Br J Cancer. 115:25–33. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Le DT, Uram JN, Wang H, Bartlett BR,
Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et
al: PD 1 blockade in tumors with mismatch-repair deficiency. N Engl
J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Van Cutsem E, Cervantes A, Adam R, Sobrero
A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson
A, Bodoky G, et al: ESMO consensus guidelines for the management of
patients with metastatic colorectal cancer. Ann Oncol.
27:1386–1422. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Giancotti FG: Mechanisms governing
metastatic dormancy and reactivation. Cell. 155:750–764. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Senft D and Ronai ZA: Adaptive stress
responses during tumor metastasis and dormancy. Trends Cancer.
2:429–442. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McLean KJ and Jacobs Lorena M: Plasmodium
falciparum Maf1 confers survival upon amino acid starvation. MBio.
8:e02317 e162017. View Article : Google Scholar
|
|
23
|
Orioli A, Praz V, Lhôte P and Hernandez N:
Human MAF1 targets and represses active RNA polymerase III genes by
preventing recruitment rather than inducing long term
transcriptional arrest. Genome Res. 26:624–635. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Whiteside TL: Immune responses to cancer:
Are they potential biomarkers of prognosis? Front Oncol. 3:1072013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Galon J, Costes A, Sanchez Cabo F,
Kirilovsky A, Mlecnik B, Lagorce Pagès C, Tosolini M, Camus M,
Berger A, Wind P, et al: Type, density, and location of immune
cells within human colorectal tumors predictclinical outcome.
Science. 313:1960–1964. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guinney J, Dienstmann R, Wang X, de
Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda
G, Angelino P, et al: The consensus molecular subtypes of
colorectal cancer. Nat Med. 21:1350–1356. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ribic CM, Sargent DJ, Moore MJ, Thibodeau
SN, French AJ, Goldberg RM, Hamilton SR, Laurent Puig P, Gryfe R,
Shepherd LE, et al: Tumor microsatellite instability status as a
predictor of benefit from fluorouracil-based adjuvant chemo therapy
for colon cancer. N Engl J Med. 349:247–257. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Weisenberger DJ, Siegmund KD, Campan M,
Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D,
Buchanan D, et al: CpG island methylator phenotype underlies
sporadic microsatellite instability and is tightly associated with
BRAF mutation in colorectal cancer. Nat Genet. 38:787–793. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
ZhangBWangJWangXZhuJLiuQShiZChambersMCZimmermanLJShaddoxKFKimSet
al NCI CPTAC: Proteogenomic characterization of human colon and
rectal cancer. Nature. 513:382–387. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Saito T, Nishikawa H, Wada H, Nagano Y,
Sugiyama D, Atarashi K, Maeda Y, Hamaguchi M, Ohkura N, Sato E, et
al: Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the
prognosis of colorectal cancers. Nat Med. 22:679–684. 2016.
View Article : Google Scholar : PubMed/NCBI
|
